Angiotensin converting enzyme inhibition: a new therapeutic modality.
作者信息
Gavras H, Charocopos F, Brunner H, Gavras I
出版信息
Bull N Y Acad Med. 1981 May;57(4):304-10.
Abstract
摘要
相似文献
1
Angiotensin converting enzyme inhibition: a new therapeutic modality.血管紧张素转换酶抑制：一种新的治疗方式。
Bull N Y Acad Med. 1981 May;57(4):304-10.
2
Angiotensin-converting enzyme inhibitors.血管紧张素转换酶抑制剂
Am Fam Physician. 1980 Nov;22(5):164-5.
3
Angiotensin inhibitors for hypertension.用于治疗高血压的血管紧张素抑制剂
Compr Ther. 1980 May;6(5):14-8.
4
Angiotensin-converting enzyme inhibition in congestive heart failure: the concept.充血性心力衰竭中的血管紧张素转换酶抑制：概念
Am J Cardiol. 1982 Apr 21;49(6):1480-3. doi: 10.1016/0002-9149(82)90364-2.
5
Coronary hemodynamic effects of angiotensin inhibition by captopril and teprotide in patients with congestive heart failure.卡托普利和替普罗肽对充血性心力衰竭患者血管紧张素抑制的冠状动脉血流动力学效应。
Am J Cardiol. 1982 Nov;50(5):967-72. doi: 10.1016/0002-9149(82)90403-9.
6
Plasma catecholamines and cardiovascular responses during converting enzyme inhibition in normotensive and hypertensive man.
Clin Exp Hypertens A. 1982;4(4-5):761-89. doi: 10.3109/10641968209061612.
7
[Some advances in angiotensin converting enzyme inhibitors].[血管紧张素转换酶抑制剂的一些进展]
Sheng Li Ke Xue Jin Zhan. 1985 Jul;16(3):229-34.
8
Monotherapy of hypertension with angiotensin-converting enzyme inhibitors.
Am J Med. 1984 Oct 5;77(4A):128-34. doi: 10.1016/s0002-9343(84)80048-0.
9
Determinants of acute and long-term response to converting enzyme inhibitors in congestive heart failure.充血性心力衰竭患者对转换酶抑制剂急性和长期反应的决定因素。
Am Heart J. 1982 Nov;104(5 Pt 2):1159-64. doi: 10.1016/0002-8703(82)90045-x.
10
[Captopril inhibits angiotensin converting enzyme. New principles for therapy in hypertension and heart failure].[卡托普利抑制血管紧张素转换酶。高血压和心力衰竭治疗的新原则]
Lakartidningen. 1981 Nov 4;78(45):4039-41.
引用本文的文献
1
Sustained haemodynamic and clinical effects of captopril in long-term treatment of severe chronic congestive heart failure.卡托普利在重度慢性充血性心力衰竭长期治疗中的持续血流动力学及临床效果
Br J Clin Pharmacol. 1982;14 Suppl 2(Suppl 2):209S-215S. doi: 10.1111/j.1365-2125.1982.tb02079.x.
本文引用的文献
1
Adverse effects of D-penicillamine in rheumatoid arthritis.青霉胺在类风湿关节炎中的不良反应。
Ann Intern Med. 1980 Jan;92(1):24-9. doi: 10.7326/0003-4819-92-1-24.
2
Disposition of captopril in normal subjects.卡托普利在正常受试者体内的处置情况。
Clin Pharmacol Ther. 1980 May;27(5):636-41. doi: 10.1038/clpt.1980.90.
3
Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure.转换酶抑制对重症充血性心力衰竭患者的持续疗效。
N Engl J Med. 1980 Jun 19;302(25):1373-9. doi: 10.1056/NEJM198006193022501.
4
Immune-complex glomerulopathy in patients treated with captopril.接受卡托普利治疗的患者的免疫复合物性肾小球病。
Lancet. 1980 Jun 7;1(8180):1212-5. doi: 10.1016/s0140-6736(80)91677-3.
5
Captopril-associated agranulocytosis.卡托普利相关性粒细胞缺乏症。
Lancet. 1980 Jan 19;1(8160):150. doi: 10.1016/s0140-6736(80)90629-7.
6
Angiotensin converting enzyme inhibition in patients with congestive heart failure.充血性心力衰竭患者的血管紧张素转换酶抑制作用
Circulation. 1978 Nov;58(5):770-6. doi: 10.1161/01.cir.58.5.770.
7
Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure.肾素-血管紧张素系统在慢性充血性心力衰竭全身血管收缩中的作用。
Circulation. 1978 Nov;58(5):763-70. doi: 10.1161/01.cir.58.5.763.
8
Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension.
JAMA. 1977 Aug 22;238(8):880-2. doi: 10.1001/jama.238.8.880.
9
Are mineralocorticoid receptors present in human renal adenocarcinoma?
Clin Sci (Lond). 1979 Nov;57(5):421-5. doi: 10.1042/cs0570421.
10
Converting enzyme inhibition in hypertensive emergencies.高血压急症中的转换酶抑制作用。
Ann Intern Med. 1979 Jan;90(1):43-7. doi: 10.7326/0003-4819-90-1-43.
Zotero 插件